Market Analysis

March 2014

Neurostimulation Devices | US | 2014 | Market Analysis

Introduction:

The US neurostimulation device market is dynamic and will expand rapidly through 2022. This market will be characterized by new indication and novel device approvals.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for neurostimulation devices in the US across a 10-year period.

Millennium Research Group has up-to-date reports on a wide range of medical device markets worldwide.

Questions Answered in This Report:

  *   Manufacturers continue to look toward new indications for current devices as a means for revenue expansion.

Which indications will be approved over the forecast period?

How will uptake of these devices in newly approved indications unfold? Which indications will see the strongest growth?

  *   Many of the currently approved indications for neurostimulation therapy have been available for a relatively long period of time.

How do volumes of higher-priced initial implants compare to replacement implants within each indication?

Given the relative distribution of initial versus replacement implants, are manufacturers targeting their marketing efforts to the appropriate physician and patient groups?

  *   Medtronic has enjoyed an unrivaled lead in a number of market segments for many years, but its position will be challenged by the entry of new competitors.

Which manufacturers—specifically within the SCS segment—have been gaining market share in recent years?

Which segments will see increased competition due to entry of new manufacturers over the forecast?

Scope:

Geographies Covered: US

Products Covered: Millennium Research Group's analysis uses the following breakdown of products in the market:

Product Type

SCS Devices

Indication

Chronic Pain

CHF

Procedure Type

Initial Implant

Replacement Implant

Product Type

Primary Cell

Rechargeable

DBS Devices

Indication

PD

Essential Tremor

Epilepsy

Dystonia

Obsessive Compulsive Disorder

Procedure Type

Initial Implant

Replacement Implant

Product Type

Primary Cell

Rechargeable

SNS Devices

Indication

UI

Fecal Incontinence

Procedure Type

Initial Implant

Replacement Implant

VNS Devices

Indication

Epilepsy

Major Depressive Disorder

CHF

Obesity

Procedure Type

Initial Implant

Replacement Implant

GES Devices

Indication

Gastroparesis

Procedure Type

Initial Implant

Replacement Implant

Competitive Analysis: Millennium Research Group provides a detailed analysis of the competitive landscape and market shares for leading competitors.
Market Forecast Features: Based on primary research with industry professionals, Millennium Research Group uses its proprietary forecasting model to provide an in-depth examination of current and future trends in unit sales, ASPs, and market values over a 10-year period (2012–2022).

Authors:

Roald Dhoska, M.A.

Contributors
Steven Edgar, M.A.
Karen Gierszewski
Samuli Heilala, M.Sc.
Veronica Ross
Kathleen Zorzella



Search Reports

Mentioned in this report:

  • BioControl Medical
  • Boston Scientific
  • Cyberonics
  • EnteroMedics
  • IntraPace
  • Medtronic
  • MetaCure
  • MicroTransponder
  • NeuroMetrix
  • NeuroPace
  • Nevro
  • Spinal Modulation
  • St. Jude Medical
  • Uroplasty
Decision Resources Group brands include: